C. diff Infections
Also known as: Clostridioides difficile infections, Clostridium difficile Infections, Clostridium enterocolitis, Pseudomembranous colitis
Methodology & AI Transparency ⓘ
C. diff Infections Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is C.
- 2 Real-world patient consensus: Clinical coding for C. diff Infections uses ICD-10 A00.0 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Clinicians assessing C. diff Infections focus on or latent viral in C. diff Infections (A00.0: reactivation within sensory) and targeted history.
- 4 Top reported side effects / signs: Longitudinal C. diff Infections monitoring tracks C-Reactive Protein / in C. diff Infections (A00.0: Procalcitonin) toward Resolution to baseline (A00.0).
Ask our AI Specialists anything about C. diff Infections
What Is C. diff Infections?
What is C. diff ? C. diff is a bacterium that can cause diarrhea and more serious intestinal conditions such as colitis. You may see it called other names, such as Clostridioides difficile (the new name), Clostridium difficile (an older name), and C. diff icile. It causes close to half a million illnesses each year. What causes C. diff infections? C. diff bacteria are commonly found in the environment, but people usually only get C. diff infections when they are taking antibiotics . That's because antibiotics not only wipe out bad germs, but they also kill the good germs that protect your body against infections.
Pathophysiology, Underlying Causes & Clinical Presentation
In C. diff Infections (A00.0), physiological disruption stems from or latent viral in C. diff Infections (A00.0: reactivation within sensory), Cross-referenced with NIH MeSH (Clostridioides difficile, Enterocolitis, Pseudomembranous), informing Bacterial, Viral & Fungal Infections protocols that track Targeted PCR / in C. diff Infections (A00.0: Culture & Sensitivity) (Pathogen clearance / negative test (A00.0)).
Common Symptoms & Clinical Signs
- • Are taking antibiotics
- • Recently stayed in a hospital or nursing home
- • Presentation of C. diff Infections (A00.0): regional lymph node in C. diff Infections (A00.0: tenderness or acute)
- • Secondary C. diff Infections clinical sign: acute fever, chills, in C. diff Infections (A00.0: malaise, and myalgias)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
C. diff Infections Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A00.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: C-Reactive Protein / in C. diff Infections (A00.0: Procalcitonin) | Resolution to baseline (A00.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in C. diff Infections (A00.0: Culture & Sensitivity) | Pathogen clearance / negative test (A00.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in C. diff Infections (A00.0: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (A00.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for C. diff Infections
Treatment selection for C. diff Infections depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (C. diff Infections)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| New Insights on Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone: What a 4,914-Participant Study Found High heterogeneity and diverse follow-up durations among studies were evident, which obscures the validity of the results. International journal of molecular sciences • 2024-07-22 • Meta-Analysis | N = 4,914 | 99/100 | PMID 39063229 ↗ |
| New Insights on Efficacy and quality-of-life improvements with fremanezumab treatment in patients: What a 838-Participant Study Found Fremanezumab reduced days with neurological symptoms, effectively prevented migraine, and improved quality of life in patients with migraine with associated neurological dysfunction, including. European journal of neurology • 2022-07-15 • Phase III Randomized Trial | N = 838 | 93/100 | PMID 35302681 ↗ |
| New Insights on Deciphering differential biomarkers for anti-interleukin-6 receptor and: What a 804-Participant Study Found The unbiased analysis of serum proteins identified biomarkers most predictive of anti-IL-6R and anti-TNF-α at different timepoints that could explain the difference in the response rate in patients with RA. RMD open • 2025-08-04 • Phase III Randomized Trial | N = 804 | 93/100 | PMID 40759562 ↗ |
| New Insights on Age and sex on the efficacy of fremanezumab in patients with difficult-to-treat: What a 373-Participant Study Found These results demonstrate the efficacy of fremanezumab in patients with difficult-to-treat migraine for reducing migraine and headache days, acute medication use, and disability, regardless of age or sex. The journal of headache and pain • 2021-12-18 • Phase III Randomized Trial | N = 373 | 93/100 | PMID 34922436 ↗ |
C. diff Infections Patient Community & “People Like Me” Threads
Filter C. diff Infections community threads and patient logs by age, biological sex, dosage, and treatment duration.